2024
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine
Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D, Madden L, Bromberg D, Haddad M, Morozova O, Ahmad B, Gómez D, Farnum S, Dvoriak S, Altice F. Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemporary Clinical Trials 2024, 146: 107690. PMID: 39265780, PMCID: PMC11531372, DOI: 10.1016/j.cct.2024.107690.Peer-Reviewed Original ResearchPrimary care centersQuality health indicatorsNon-communicable diseasesSpecialty treatment centersOpioid agonist therapyImplementation of integrated carePay-for-performance incentivesPrimary care clinicsPrimary care settingSelf-reported prevalencePay-for-performancePrevalence of medical comorbiditiesParticipants self-reportedEffective evidence-based treatmentsHealth of PWIDEvidence-based treatmentsIntegrated careCare clinicsImplementation outcomesImplementation trialCare settingsElectronic chart reviewHigh-burden countriesSpecialty servicesHIV prevalenceIntegrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge
Bromberg D, Machavariani E, Madden L, Dumchev K, LaMonaca K, Earnshaw V, Pykalo I, Filippovych M, Haddad M, Dvoriak S, Altice F. Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal Of The International AIDS Society 2024, 27: e26202. PMID: 38379179, PMCID: PMC10879646, DOI: 10.1002/jia2.26202.Peer-Reviewed Original ResearchConceptsPrimary care clinicsStigma reduction interventionsOpioid agonist therapyClinicians' attitudesStigma constructsHIV preventionReduction interventionsEvidence-based HIV preventionCluster randomized controlled trialEvidence-based carePrimary care settingIntegrated care sitesDirect providersRandomized controlled trialsProvider stigmaCare clinicsCare sitesHIV careCare settingsHealth outcomesClinical staffSubstance use disordersLinear mixed-effects modelsTreatment continuumImprove attitudes
2023
Clinic-Integrated Smartphone App (JomPrEP) to Improve Uptake of HIV Testing and Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Malaysia: Mixed Methods Evaluation of Usability and Acceptability
Shrestha R, Altice F, Khati A, Azwa I, Gautam K, Gupta S, Sullivan P, Ni Z, Kamarulzaman A, Phiphatkunarnon P, Wickersham J. Clinic-Integrated Smartphone App (JomPrEP) to Improve Uptake of HIV Testing and Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Malaysia: Mixed Methods Evaluation of Usability and Acceptability. JMIR MHealth And UHealth 2023, 11: e44468. PMID: 36795465, PMCID: PMC9982718, DOI: 10.2196/44468.Peer-Reviewed Original ResearchConceptsHIV prevention servicesINTERNATIONAL REGISTERED REPORT IDENTIFIERPrevention servicesMean ageHIV preventionPre-exposure prophylaxisHIV prevention outcomesHIV self-testing (HIVST) kitsParticipants' mean ageSelf-testing kitsHealth care settingsMobile health platformMalaysian MSMMixed-methods evaluationHIV testingCare settingsLocal clinicSystem Usability ScalePrevention outcomesDays of testingMSMSmartphone appPrEPHIVMean score
2021
Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study
Meteliuk A, Galvez S, Fomenko T, Kalandiia H, Iaryi V, Farnum SO, Islam Z, Altice FL, Madden LM. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Journal Of Substance Use And Addiction Treatment 2021, 134: 108619. PMID: 34579978, DOI: 10.1016/j.jsat.2021.108619.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyPrimary care clinicsPrimary care settingOAT coverageAgonist therapyStable patientsCare clinicsSubstance useCare settingsNegative urine drug testsSpecialty addictions treatmentUrine drug testsSymptom Identification ScaleMental health symptomsAddiction treatment clinicsHIV transmissionPrimary careTreatment clinicsOAT patientsBASIS-24PatientsHealth symptomsEmotional labilityAddiction treatmentPilot study
2018
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCare
2017
An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru
Weikum D, Shrestha R, Ferro EG, Vagenas P, Copenhaver M, Spudich S, Alpert MD, Cabello R, Lama JR, Sanchez J, Altice FL. An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. AIDS Care 2017, 29: 1297-1301. PMID: 28449599, PMCID: PMC6337065, DOI: 10.1080/09540121.2017.1322681.Peer-Reviewed Original ResearchConceptsHIV-positive menNeuropsychological Impairment ScaleNeurocognitive impairmentTransgender womenAntiretroviral therapyHIV-positive MSMPoor clinical outcomeHIV risk behaviorsClinical care settingsHealth-related outcomesExploratory factor analysisART adherenceClinical outcomesPatient populationCare settingsImpairment ScaleRisk behaviorsImpairmentMenPrincipal axis factoringSelf-report scalesOrthogonal varimax rotationWomenBrief self-report scaleOutcomes
2016
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment
Bojko MJ, Mazhnaya A, Marcus R, Makarenko I, Islam Z, Filippovych S, Dvoriak S, Altice FL. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment. Journal Of Substance Use And Addiction Treatment 2016, 66: 37-47. PMID: 27211995, PMCID: PMC4919997, DOI: 10.1016/j.jsat.2016.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidDelivery of Health CareFemaleFocus GroupsGrounded TheoryHumansMaleOpiate Substitution TreatmentOpioid-Related DisordersPatient Acceptance of Health CarePractice Guidelines as TopicPractice Patterns, Physicians'Quality ImprovementSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyOAT retentionAgonist therapyTreatment goalsAdditional patient educationRealistic treatment goalsPrimary care settingQuality improvement interventionsCommunity-level barriersPatient educationOpioid addictionCare settingsTreatment retentionMultilevel barriersTreatment settingsImprovement interventionsPWIDMedical staffTherapyTreatmentCommunity awarenessDelivery barriersExperiences of PWIDHigh attritionFocus groupsAn Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy
Copenhaver M, Shrestha R, Wickersham JA, Weikum D, Altice FL. An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. Journal Of Substance Use And Addiction Treatment 2016, 63: 61-65. PMID: 26879859, PMCID: PMC4775373, DOI: 10.1016/j.jsat.2016.01.002.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyNeuropsychological Impairment ScaleNeurocognitive impairmentMaintenance therapySex-related HIV risk behaviorsHIV risk behaviorsClinical care settingsNeuro-cognitive impairmentExploratory factor analysisCare settingsImpairment ScaleRisk behaviorsAddiction treatmentBrief self-report scaleImpairmentSelf-report measuresSelf-report scalesPatientsPrincipal axis factoringCognitive functioningTherapyFactor analysisOrthogonal varimax rotationPresent studyPotential utility
2011
Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARVHIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s22-s32. PMID: 21317590, PMCID: PMC3263431, DOI: 10.1097/qai.0b013e318209751e.Peer-Reviewed Original ResearchConceptsBUP/NXHIV treatment outcomesCD4 lymphocyte countHIV clinical care settingsAntiretroviral therapyViral suppressionLymphocyte countTreatment outcomesClinical care settingsOpioid dependenceCare settingsLower HIV-1 RNA levelsBuprenorphine/naloxone treatmentHIV-1 RNA levelsInitiation of ARTHIV-1 RNA suppressionComorbid substance use disorderHealth qualityBuprenorphine/naloxoneMultidisciplinary treatment strategyOpioid-dependent patientsGeneral health qualityMental health qualityOpioid-dependent subjectsSubstance use disorders
2009
Comparison of Tuberculin Skin Testing Reactivity in Opioid-Dependent Patients Seeking Treatment with Methadone versus Buprenorphine: Policy Implications for Tuberculosis Screening
Schwarz RK, Bruce RD, Ball SA, Herme M, Altice FL. Comparison of Tuberculin Skin Testing Reactivity in Opioid-Dependent Patients Seeking Treatment with Methadone versus Buprenorphine: Policy Implications for Tuberculosis Screening. The American Journal Of Drug And Alcohol Abuse 2009, 35: 439-444. PMID: 20014914, DOI: 10.3109/00952990903447741.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentTuberculin skin testingBuprenorphine maintenance treatmentOpioid-dependent patientsTST positivityMaintenance treatmentBMT programRetrospective cohort studyPrimary care settingSimilar high prevalenceCross-sectional analysisEthnic health disparitiesBMT patientsBMT settingCohort studyTuberculosis infectionSkin testingTuberculosis screeningTST resultsMMT programPatient populationPrimary careHigh prevalenceCare settingsPatients
2006
Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 2006, 43: s169-s172. PMID: 17109302, DOI: 10.1086/508179.BooksMeSH KeywordsAntiretroviral Therapy, Highly ActiveBuprenorphineDelivery of Health Care, IntegratedFemaleFollow-Up StudiesHealth Services ResearchHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersPrimary Health CarePrimary PreventionRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesConceptsHuman immunodeficiency virusDrug abuseCare settingsTreatment of HIVHIV primary care settingPrimary HIV care settingsMental Health Services AdministrationHIV primary careProvision of buprenorphineActive antiretroviral therapyHIV care settingsPrimary care settingCollaborative HIV ResearchHealth Services AdministrationAddiction/dependenceAntiretroviral therapyHIV infectionImmunodeficiency syndromeImmunodeficiency virusPrimary careSuccessful treatmentDrug abusersHIV researchDisease controlSubstance abuseThe Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individualsModels for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Basu S, Rohrberg D, Bruce RD, Altice FL. Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting. Clinical Infectious Diseases 2006, 42: 716-721. PMID: 16447120, DOI: 10.1086/500200.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyHIV care settingsMaintenance therapyHIV servicesCare settingsPrimary HIV care settingsSite specialistHIV care providersInjection drug useHuman immunodeficiency virusNegative clinical outcomesPrimary care modelDrug treatment modelAntiretroviral therapyHIV careBuprenorphine therapyClinical outcomesImmunodeficiency virusClinic settingOpiate useCare modelCare providersOpiate dependenceDrug useTherapy services
1998
Adherence to Antiretroviral Therapy in Correctional Settings
Altice F, Buitrago M. Adherence to Antiretroviral Therapy in Correctional Settings. Journal Of Correctional Health Care 1998, 5: 179-200. DOI: 10.1177/107834589800500205.Peer-Reviewed Original ResearchAntiretroviral therapyNew antiretroviral combinationsDrug-resistant HIVLack of benefitHealth care settingsCorrectional settingsAntiretroviral combinationsClinical benefitHIV progressionCare existFaceted interventionHIV therapyCare settingsDrug usersTherapyAIDS incidenceHIVAdherenceCorrectional environmentSettingHospitalizationPatientsDramatic decreaseCliniciansIncidence